Pancreatic Cancer Market Analysis

Type (Chemotherapy, Targeted Therapy)

The chemotherapy segment is estimated to account for 55% share of the global pancreatic cancer market in the year 2037. The increasing use of chemotherapy and targeted therapy for cancer cell isolation in tumor formation is estimated to propel the market segment growth as per the market analysis. The rising presence of competent practitioners and increasing medical facilities for providing chemotherapy across the world are expected to drive market segment growth in the coming years. More than 26% of people across the UK are estimated to have chemotherapy as the primary treatment for pancreatic cancer as of 2020.

Affected Area (Exocrine, Endocrine)

The exocrine segment is expected to hold 60% of the revenue share by 2037. The pancreas is mostly composed of exocrine cells compared to endocrine cells in the body is estimated to drive the market segment growth. The growth of the segment is attributed to the increasing prevalence of exocrine cancers. More than 90% of pancreatic cancers across the world are exocrine tumours as of estimations in 2022. Cancer in the ducts affects the exocrine cells of the pancreas causing exocrine cancer and is estimated to drive market growth across the world.

Our in-depth analysis of the global market includes the following segments: